Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides | Zendy

Pablo Vieyra-Garcia | Zendy; Regina FinkPuches | Zendy; Stefanie Porkert | Zendy; Roland Lang | Zendy; Sophie Pöchlauer | Zendy; Gudrun Ratzinger | Zendy; Adrian Tanew | Zendy; Sylvia Selhofer | Zendy; Paul-Gunther Sator | Zendy; Angelika Hofer | Zendy; Alexandra GruberWackernagel | Zendy; Franz J. Legat | Zendy; VijayKumar Patra | Zendy; Franz Quehenberger | Zendy; Lorenzo Cerroni | Zendy; Rachael A. Clark | Zendy; Peter Wolf | Zendy

Open Access

Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides

Author(s) -

Pablo Vieyra-Garcia,

Regina FinkPuches,

Stefanie Porkert,

Roland Lang,

Sophie Pöchlauer,

Gudrun Ratzinger,

Adrian Tanew,

Sylvia Selhofer,

Paul-Gunther Sator,

Angelika Hofer,

Alexandra GruberWackernagel,

Franz J. Legat,

VijayKumar Patra,

Franz Quehenberger,

Lorenzo Cerroni,

Rachael A. Clark,

Peter Wolf

Publication year - 2019

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.5905

Subject(s) - mycosis fungoides , medicine , psoralen , regimen , puva therapy , dermatology , population , stage (stratigraphy) , randomized controlled trial , maintenance therapy , clinical endpoint , surgery , chemotherapy , psoriasis , lymphoma , dna , paleontology , environmental health , biology , genetics

Psoralen-UV-A (PUVA) photochemotherapy is standard first-line treatment for skin-limited, early-stage mycosis fungoides capable of producing high initial complete response (CR) rates. However, much remains unknown about PUVA's therapeutic mechanisms, optimal duration and frequency of treatment, dose escalation, or use as maintenance therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research